CASPIAN

NCT03043872 📎

Regimen

Experimental
durvalumab + platinum-etoposide (EP/EC)
Control
platinum-etoposide (EP/EC)

Population

Treatment-naive extensive-stage small-cell lung cancer

Key finding

mOS 13.0 vs 10.3 mo (HR 0.73, 95% CI 0.59-0.91, P=0.0047); 18-mo OS 34% vs 25%

Source: PMID 31590988

Timeline

    Guideline citations

    • NCCN SCLC (p.25)
    • CSCO SCLC 2025 (p.64)⚠️ OCR source